132076-27-8 Usage
Description
Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (R)(9CI), also known as (R)-3-Oxo-cyclopentanecarboxylic acid methyl ester, is a synthetic intermediate that plays a crucial role in the pharmaceutical industry. It is an organic compound derived from cyclopentanecarboxylic acid, featuring a methyl ester group and a 3-oxo functional group. Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (R)(9CI) is characterized by its potential to be used in the synthesis of various pharmaceutical compounds, making it a valuable asset in drug development.
Uses
Used in Pharmaceutical Synthesis:
Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (R)(9CI) is used as a synthetic intermediate for pharmaceutical synthesis. Its unique structure and functional groups make it a versatile building block for the development of new drugs and therapeutic agents. The compound's ability to be incorporated into various molecular frameworks allows researchers to explore its potential in creating novel pharmaceutical compounds with improved efficacy and safety profiles.
Used in Drug Development:
In the field of drug development, Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (R)(9CI) serves as a key component in the design and synthesis of new drug candidates. Its presence in the molecular structure can influence the pharmacokinetic and pharmacodynamic properties of the resulting compounds, potentially leading to more effective treatments for various diseases and conditions. By utilizing this synthetic intermediate, researchers can optimize the drug discovery process and accelerate the development of innovative therapeutic solutions.
Used in Medicinal Chemistry Research:
Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (R)(9CI) is also employed in medicinal chemistry research, where it is used to study the structure-activity relationships of various drug candidates. By incorporating this compound into different molecular frameworks, researchers can gain insights into the factors that contribute to a compound's biological activity, selectivity, and potency. This information can then be used to guide the design of more effective and targeted therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 132076-27-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,0,7 and 6 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 132076-27:
(8*1)+(7*3)+(6*2)+(5*0)+(4*7)+(3*6)+(2*2)+(1*7)=98
98 % 10 = 8
So 132076-27-8 is a valid CAS Registry Number.
132076-27-8Relevant articles and documents
Asymmetric Synthesis of N-Substituted γ-Amino Esters and γ-Lactams Containing α,γ-Stereogenic Centers via a Stereoselective Enzymatic Cascade
Li, Ming,Cui, Yunfeng,Xu, Zefei,Chen, Xi,Feng, Jinhui,Wang, Min,Yao, Peiyuan,Wu, Qiaqing,Zhu, Dunming
, p. 372 - 379 (2021/10/25)
γ-Amino esters and γ-lactams containing α,γ-stereogenic centers are widely used as chiral intermediates in various bioactive compounds, while their efficient synthesis remains a challenge. Herein, an enzymatic cascade reaction involving an ene reductase (
Biocatalytic access to nonracemic γ-oxo esters: Via stereoselective reduction using ene-reductases
Turrini, Nikolaus G.,Cioc, Rǎzvan C.,Van Der Niet, Daan J. H.,Ruijter, Eelco,Orru, Romano V. A.,Hall, Mélanie,Faber, Kurt
, p. 511 - 518 (2017/08/14)
The asymmetric bioreduction of α,β-unsaturated γ-keto esters using ene-reductases from the Old Yellow Enzyme family proceeds with excellent stereoselectivity and high conversion levels, covering a broad range of acyclic and cyclic derivatives. Various strategies were employed to provide access to both enantiomers, which are versatile precursors of bioactive molecules. The regioselectivity of hydride addition on di-activated alkenes was elucidated by isotopic labeling experiments and showed strong preference for the keto moiety as activating/binding group as opposed to the ester. Finally, chemoenzymatic synthesis of (R)-2-(2-oxocyclohexyl)acetic acid was achieved in high ee on a preparative scale combining enzymatic reduction followed by ester hydrogenolysis.
ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
-
Paragraph 0215, (2018/01/20)
The present invention relates to novel adenine based inhibitors of adenylyl cyclase of the formula: wherein X, L, R1, R2, R5 are those defined herein. Compounds of the present invention are useful to treat cardiovascular diseases. The present invention also relates to a method of preventing heart failure by administering an effective amount of compound according to the invention following vascular injury and reperfusion therapy.
